Literature DB >> 11491216

Thoracic actinomycosis (arcanobacteriosis) or nocardiosis causing thoracic pyogranuloma formation in three dogs.

R K Sivacolundhu1, A J O'Hara, R A Read.   

Abstract

OBJECTIVE: To describe three cases of canine thoracic actinomycosis (arcanobacteriosis) or nocardiosis in which the primary pathological lesion was a pyogranulomatous abscess in the mediastinum. Clinical signs, difficulties in diagnosis, treatment and prognosis are examined. Comparisons are made between human and veterinary literature to assist in formulating a rational treatment plan.
DESIGN: Retrospective clinical study. PROCEDURE: Review of case records from 1984 to 1998.
RESULTS: Three dogs presented with large intrathoracic pyogranulomas producing variable clinical signs, not necessarily associated with the respiratory tract. Ages ranged from 2 to 5 years old. Two dogs responded to surgical opening and passive drainage of the abscess, or surgical excision of the granuloma with associated structures, and medical therapy. One dog died intra-operatively.
CONCLUSION: A combination of surgical and antimicrobial therapy may carry a fair-to-good prognosis for thoracic granuloma caused by actinomycosis (arcanobacteriosis) or nocardiosis. The extent of surgery should be based on assessment of individual cases and must include surgical biopsy for histology and culture to enable a specific diagnosis to be made. Complete surgical excision is not necessarily required. Prolonged antimicrobial therapy is indicated.

Entities:  

Mesh:

Year:  2001        PMID: 11491216     DOI: 10.1111/j.1751-0813.2001.tb12981.x

Source DB:  PubMed          Journal:  Aust Vet J        ISSN: 0005-0423            Impact factor:   1.281


  2 in total

1.  Actinomyces endophthalmitis and pneumonia in a dog.

Authors:  Laura D Barnes; Bruce H Grahn
Journal:  Can Vet J       Date:  2007-11       Impact factor: 1.008

2.  Nonsurgical resolution of caudal mediastinal paraesophageal abscess in a cat.

Authors:  Joohyun Jung; Mincheol Choi
Journal:  J Vet Med Sci       Date:  2014-12-27       Impact factor: 1.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.